All In Biotech

Drug Trial Radar · NCT07360080

Long-Term Outcomes of Teplizumab in Routine Clinical Care

Long-Term Outcomes of Participants Treated With Teplizumab in Routine Clinical Care

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Mar 19, 2026

Primary completion

Oct 29, 2035

Study completion Oct 29, 2035

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more comprehensive understanding of how the treatment performs over time and across diverse patient populations, providing valuable insights into the sustained effects of teplizumab and offering a real world picture of its impact on the long-term management of T1D.

Conditions

  • Type 1 Diabetes

Interventions

  • TeplizumabDrug

    This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from teplizumab infusion start to the onset of Stage 3 T1DTime frame: From start of infusion to maximum of 10 years

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • Investigational Site Number: 8400006

    Washington D.C., District of Columbia · Recruiting

  • Investigational Site Number: 8400003

    Atlanta, Georgia · Recruiting

  • Investigational Site Number: 8400004

    Atlanta, Georgia · Recruiting

  • Investigational Site Number: 8400001

    New York, New York · Recruiting

  • Investigational Site Number: 8400002

    Syosset, New York · Recruiting

  • Investigational Site Number: 8400005

    Sandy City, Utah · Recruiting

  • Investigational Site Number: 2760004

    Hanover, Germany · Recruiting

  • Investigational Site Number: 3760003

    Petah Tikva, Israel · Recruiting

  • Investigational Site Number: 3760002

    Ramat Gan, Israel · Recruiting

  • Investigational Site Number: 3760001

    Ramat Gan, Israel · Recruiting

  • Investigational Site Number: 7840001

    Abu Dhabi, United Arab Emirates · Recruiting

  • Investigational Site Number: 7840002

    Abu Dhabi, United Arab Emirates · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.